Skip to Main Content

Author Details

Mark S Anderson
Diabetes Center, University of California san francisco
2017
32
16
Nevan J Krogan (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36860908Spectrum of Clinical Presentations, Imaging Findings, and HLA Types in Immune Checkpoint Inhibitor-Induced Hypophysitis.J Endocr Soc2023
37520758ABCC8-Related Monogenic Diabetes Presenting Like Type 1 Diabetes in an Adolescent.AACE Clin Case Rep2023
37237059A genomic data archive from the Network for Pancreatic Organ donors with Diabetes.Sci Data2023
37463205T cell deletional tolerance restricts AQP4 but not MOG CNS autoimmunity.Proc Natl Acad Sci U S A2023
36920087Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial.Diabetes Care2023
36875114Case report: Discovery of a <i>de novo FAM111B</i> pathogenic variant in a patient with an APECED-like clinical phenotype.Front Immunol2023
36798288Autoantigen profiling reveals a shared post-COVID signature in fully recovered and Long COVID patients.medRxiv2023
35037050Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Transmission Dynamics and Immune Responses in a Household of Vaccinated Persons.Clin Infect Dis2022
36527083Prevalence of type-1 interferon autoantibodies in adults with non-COVID-19 acute respiratory failure.Respir Res2022
35925682Immune cells and their inflammatory mediators modify β cells and cause checkpoint inhibitor-induced diabetes.JCI Insight2022
36151471Publisher Correction: A RORγt<sup>+</sup> cell instructs gut microbiota-specific T<sub>reg</sub> cell differentiation.Nature2022
35043109The risk of COVID-19 death is much greater and age-dependent with type I IFN autoantibodies.Res Sq2022
32886542Autoimmune Endocrinopathies: An Emerging Complication of Immune Checkpoint Inhibitors.Annu Rev Med2021
33758859Longitudinal single-cell epitope and RNA-sequencing reveals the immunological impact of type 1 interferon autoantibodies in critical COVID-19: Anti-IFN antibodies in critical COVID-19 correlate with poor ISG response and upregulation of LAIR1 surface protein in PBMCs.bioRxiv2021
33890986Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1.J Exp Med2021
34529475Response to Comments on "Aberrant type 1 immunity drives susceptibility to mucosal fungal infections".Science2021
34429372Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19.Sci Transl Med2021
34009544Neutralizing Autoantibodies to Type I Interferons in COVID-19 Convalescent Donor Plasma.J Clin Immunol2021
34009124Single-cell transcriptome analysis defines heterogeneity of the murine pancreatic ductal tree.Elife2021
34172489Diabetes With Multiple Autoimmune and Inflammatory Conditions Linked to an Activating SKAP2 Mutation.Diabetes Care2021
33446526Aberrant type 1 immunity drives susceptibility to mucosal fungal infections.Science2021
32511497Test performance evaluation of SARS-CoV-2 serological assays.medRxiv2020
32027018Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes.Clin Exp Immunol2020
32855547Evaluation of SARS-CoV-2 serology assays reveals a range of test performance.Nat Biotechnol2020
32964173Breaking β Cell Tolerance After 100 Years of Life: Intratumoral Immunotherapy-Induced Diabetes Mellitus.J Endocr Soc2020
32954318High-resolution epitope mapping of anti-Hu and anti-Yo autoimmunity by programmable phage display.Brain Commun2020
30885563Checkpoint inhibitor-induced insulin-dependent diabetes: an emerging syndrome.Lancet Diabetes Endocrinol2019
29025879<i>TCF7L2</i> Genetic Variants Contribute to Phenotypic Heterogeneity of Type 1 Diabetes.Diabetes Care2018
29937434Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors.Diabetes2018
30275285Transcription Factor 7-Like 2 (<i>TCF7L2</i>) Gene Polymorphism and Progression From Single to Multiple Autoantibody Positivity in Individuals at Risk for Type 1 Diabetes.Diabetes Care2018
28770323Understanding and preventing type 1 diabetes through the unique working model of TrialNet.Diabetologia2017
28948305Erratum to: Understanding and preventing type 1 diabetes through the unique working model of TrialNet.Diabetologia2017
  • 1 - 32 of 32

Recommended Authors

Jillian P Rhoads
Vanderbilt University Medical Center
Career Start Year 2015
Number of shared co-authors 0
Haolong Li
University of California san francisco
Career Start Year 2014
Number of shared co-authors 0
Ang Cui
Massachusetts Institute of Technology
Career Start Year 2013
Number of shared co-authors 0
Jerill Thorpe
Benaroya Research Institute at Virginia Mason
Career Start Year 2011
Number of shared co-authors 6
Alexander F Rosenberg
University of Alabama at Birmingham Birmingham
Career Start Year 2011
Number of shared co-authors 0
Ya??ma L Lightfoot
The University of Texas MD Anderson Cancer Center
Career Start Year 2011
Number of shared co-authors 4
Matthew J Dufort
Center for Systems Immunology, Benaroya Research Institute Seattle
Career Start Year 2011
Number of shared co-authors 5
Timothy Chu
University of California Riverside
Career Start Year 2010
Number of shared co-authors 0
Klara R Klein
University of North Carolina School of Medicine
Career Start Year 2010
Number of shared co-authors 1
Philip Brohawn
MedImmune LLC
Career Start Year 2009
Number of shared co-authors 0
Alice E Wiedeman
Center for Translational Immunology, Benaroya Research Institute at Virginia Mason
Career Start Year 2007
Number of shared co-authors 6
Howard R Seay
College of Medicine, Diabetes Institute, University of Florida
Career Start Year 2007
Number of shared co-authors 6
John R Mills
Mayo Clinic
Career Start Year 2007
Number of shared co-authors 4
Kristina M Harris
University of California san francisco
Career Start Year 2006
Number of shared co-authors 6
Avi Z Rosenberg
Johns Hopkins University
Career Start Year 2006
Number of shared co-authors 0
Aaron M Ring
Yale University School of Medicine
Career Start Year 2006
Number of shared co-authors 9
Brandon W Higgs
Translational and Clinical Data Sciences
Career Start Year 2006
Number of shared co-authors 0
Shari Messinger
University of Miami Miller School of Medicine
Career Start Year 2004
Number of shared co-authors 1
Johnna D Wesley
Novo Nordisk Research Center Seattle, Inc.
Career Start Year 2003
Number of shared co-authors 4
Andrew Wang
Yale University School of Medicine
Career Start Year 2001
Number of shared co-authors 0
Fahd Al-Mulla
Dasman Diabetes Institute
Career Start Year 1998
Number of shared co-authors 0
Seunghee Kim-Schulze
Icahn School of Medicine at Mount Sinai
Career Start Year 1996
Number of shared co-authors 1
Vivian H Gersuk
Center for Systems Immunology, Benaroya Research Institute
Career Start Year 1993
Number of shared co-authors 8
Michael J Clare-Salzler
University of Florida College of Medicine
Career Start Year 1989
Number of shared co-authors 6
Teresa P DiLorenzo
Universidad Cardenal Herrera-CEU, CEU Universities
Career Start Year 1989
Number of shared co-authors 1
Nir Hacohen
Broad Institute of MIT and Harvard
Career Start Year 1989
Number of shared co-authors 7
Maura Rossetti
University of California Los Angeles
Career Start Year 1986
Number of shared co-authors 0
Karen Cerosaletti
Center for Translational Immunology
Career Start Year 1985
Number of shared co-authors 8
Martin S Zand
University of Rochester Medical Center
Career Start Year 1983
Number of shared co-authors 1
Richard David Leslie
Blizard Institute, Barts and Royal London Medical School
Career Start Year 1977
Number of shared co-authors 2

Collaborators

Joseph L DeRisi
University of California San Francisco
Co-authored papers 7
Kevan C Herold
Yale University
Co-authored papers 6
Carla J Greenbaum
Center for Interventional Immunology, Benaroya Research Institute at Virginia Mason
Co-authored papers 4
Kara L Lynch
University of California San Francisco
Co-authored papers 4
Michael R Wilson
Weill Institute for Neurosciences, University of California-San Francisco
Co-authored papers 4
Chun Jimmie Ye
University of California san francisco
Co-authored papers 3
Larry J Dumont
Vitalant Research Institute
Co-authored papers 3
Carolyn S Calfee
University of California San Francisco
Co-authored papers 3
Jeffrey D Whitman
University of California San Francisco School of Medicine
Co-authored papers 3
Philip J Norris
Vitalant Research Institute
Co-authored papers 3
Jochen K Lennerz
Massachusetts General Hospital/Harvard Medical School
Co-authored papers 2
Dianna L Ng
Memorial Sloan Kettering Cancer Center
Co-authored papers 2
Jane H Buckner
Center for Translational Immunology, Benaroya Research Institute at Virginia Mason
Co-authored papers 2
Charles Y Chiu
University of California-San Francisco
Co-authored papers 2
Justine Levan
University of California San Francisco
Co-authored papers 2
Stefania Pittaluga
National Cancer Institute, National Institutes of Health
Co-authored papers 2
Youjin V Lee
University of Chicago
Co-authored papers 2
Nevan J Krogan (CM4AI)
University of California San Francisco
Co-authored papers 2
Edward T Ryan
Massachusetts General Hospital
Co-authored papers 2
Gregory M Goldgof
University of California san francisco
Co-authored papers 2
Jackie Chan
University of California san francisco
Co-authored papers 2
Mary E Moreno
San Francisco General Hospital, University of California
Co-authored papers 2
Antonia E Gallman
Yale University School of Medicine
Co-authored papers 2
Trisha A Macrae
University of California san francisco
Co-authored papers 2
Zachary Steinhart
Gladstone-UCSF Institute of Genomic Immunology
Co-authored papers 2
Eva M Gillis-Buck
University of California san francisco
Co-authored papers 2
Nicolas Bouladoux
National Institute of Allergy and Infectious Diseases
Co-authored papers 2
Than S Kyaw
University of California san francisco
Co-authored papers 2
Jason G Cyster
University of California san francisco
Co-authored papers 2
Aashish Manglik
Department of Pharmaceutical Chemistry, University of California San Francisco
Co-authored papers 2
Release 1.2